CDEK
← All drugs Report issue

tazobactam

Trade name: Zosyn

Small moleculeapproved

Approved

Oct 22, 1993

Tazobactam is a beta-lactamase inhibitor, which was approved by FDA for the treatment of wide range of bacterial infections either in combination with piperacillin (Zosyn) or with ceftolozane (Zerbaxa). — NCATS

Clinical trial activity

120 trials · 171 clinical orgs · 27 marketing orgs

Phase 1
15
Phase 2
48
Phase 3
37
Phase 4
37

Earliest trial started Nov 1, 1997 (NCT00003805)

Timeline

1990s

  1. Oct 22, 1993

    Earliest FDA Approval

  2. Oct 22, 1993

    Wyeth — NDA Secondary Org

  3. Oct 22, 1993

    American Home Products — NDA Secondary Org

  4. Jan 1, 1997

    Earliest Phase 3 Sponsor(trial)

  5. Feb 24, 1998

    Baxalta — NDA Secondary Org

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

  3. Sep 15, 2009

    Hospira — Marketing Organization

2010s

  1. Oct 21, 2010

    Sandoz — Marketing Organization

  2. Oct 21, 2010

    Novartis — Marketing Organization

  3. May 23, 2011

    Aurobindo Pharma — Marketing Organization

  4. May 23, 2011

    Eugia Pharma — Marketing Organization

  5. May 31, 2011

    Istituto Bio Ita Spa — Marketing Organization

  6. Aug 15, 2014

    Mylan — Marketing Organization

  7. Aug 15, 2014

    STERISCIENCE — Marketing Organization

  8. Aug 15, 2014

    ONESOURCE SPECIALTY — Marketing Organization

  9. Dec 19, 2014

    Cubist — NDA Secondary Org

  10. Dec 19, 2014

    Merck — NDA Secondary Org

  11. Jan 13, 2017

    Apollo Hospitals, Chennai, India — Marketing Organization

  12. Jan 13, 2017

    Provepharm Sas — Marketing Organization

  13. Jan 13, 2017

    Apollo Pharmacy — Marketing Organization

  14. Jan 13, 2017

    Milla Pharms — Marketing Organization

  15. Mar 17, 2017

    Wockhardt — Marketing Organization

  16. Mar 17, 2017

    Apotex — Marketing Organization

  17. May 11, 2018

    Fresenius — Marketing Organization

  18. Aug 10, 2018

    Qilu Pharmaceutical Co., Ltd. — Marketing Organization

  19. Aug 10, 2018

    Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization

  20. Jul 29, 2019

    Astral — Marketing Organization

2020s

  1. Feb 16, 2021

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  2. Feb 16, 2021

    Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization

  3. Apr 3, 2025

    B. Braun — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

Combination products

  • zerbaxa

    with ceftolozane

    Also known as ceftolozane and tazobactam

  • zosyn

    with piperacillin

    Also known as piperacillin and tazobactam

Approval history

  • approvedOct 22, 1993

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
Mol. weight
300.3 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • ceftolozane sulfate / tazobactam sodium
  • cl-298741
  • cl-298741
  • cl-298741
  • taszobactam sodium
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam
  • tazobactam sodium
  • tazobactam sodium
  • tazobactam sodium
  • tazocel
  • ytr 830
  • ytr 830
  • ytr-830
  • ytr-830
  • ytr 830h
  • ytr-830h
  • ytr-830h
  • ytr-830h

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06954129Phase 4Oct 31, 2025University of Pennsylvania
NCT06712641Phase 4Jun 30, 2025Oslo Metropolitan University, University of Oslo
NCT06342115Phase 4Oct 31, 2024Beneficência Portuguesa de Sao Paulo, Merck
NCT06123169Phase 3Mar 31, 2024Rouen Normandy University
NCT06293677Phase 4Mar 1, 2024University of Lausanne
NCT06184659Phase 4Mar 1, 2024Scandinavian Critical Care Trials Group
NCT05943223Phase 2Jan 31, 2024McMaster University
NCT07096310Phase 1/Phase 2 (Phase 2)Jan 1, 2024Ain Shams University
NCT05753735Phase 2Dec 20, 2023Case Western Reserve University
NCT06422533N/ANov 7, 2023Government of Mexico
NCT06035055Phase 4Oct 31, 2023Sunshine Coast Hospital and Health Service, Sunshine Coast University, Australia, University of Queensland
NCT05981079Phase 4Jul 31, 2023Hebei University, Liaocheng People's Hospital, Nanjing Medical University, Qingdao University, Shandong Province Qianfoshan Hospital, Shandong Provincial Hospital, Shandong University, Shengli Oilfield Central Hospital, Tai'an Central Hospital
NCT05565222Phase 3Jan 31, 2023Assistance Publique - Hôpitaux de Paris
NCT05355350Phase 4Jul 1, 2022Hebrew University, Technion University, Tel Aviv University
NCT05061654Phase 4Feb 28, 2022Hamad Medical Corporation, Merck
NCT05102162Phase 4Dec 31, 2021Food and Drug Administration, University of Florida
NCT05060419Phase 2Oct 8, 2021Fudan University, Qilu Pharmaceutical Co., Ltd.
NCT04816968Phase 1Sep 30, 2021Revert ONLUS, University of Milan
NCT04983901Phase 2Sep 14, 2021University of Texas at Houston
NCT04948463Phase 4Jul 31, 2021Murdoch University
Showing 20 of 120 trials
Page 1 / 6

Organizations

Research & Development (171)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit221242001
CubistFor profit7642010
PfizerFor profit6522000
WyethFor profit5022000
Tel Aviv UniversityAcademic/Hospital4222009
University of QueenslandAcademic/Hospital4322014
Medpace, Inc.For profit3012016
University of Texas at HoustonAcademic/Hospital3312018
WockhardtFor profit3322016
Ain Shams UniversityAcademic/Hospital2222018
BayerFor profit2112005
ClinartisFor profit2012016
Duke UniversityAcademic/Hospital2222009
Fundación Pública AndaluzaAcademic/Hospital2212011
Ghent UniversityAcademic/Hospital2212016
Government of MexicoGovernment2212017
Indiana UniversityAcademic/Hospital2022015
Nanjing Medical UniversityAcademic/Hospital2122012
Ohio State UniversityAcademic/Hospital2122014
People's Liberation Army of ChinaGovernment2212012
171 organizations
Page 1 / 9

Marketing (33)

OrganizationOrg typeRelationshipDate
American Home ProductsFor profitNDA2Oct 22, 1993
Apollo Hospitals, Chennai, IndiaAcademic/HospitalMKTGJan 13, 2017
Apollo PharmacyAcademic/HospitalMKTGJan 13, 2017
ApotexFor profitMKTGMar 17, 2017
AstralFor profitMKTGJul 29, 2019
Aurobindo PharmaFor profitMKTGMay 23, 2011
B. BraunFor profitNDA2Apr 3, 2025
BaxaltaFor profitNDA2Feb 24, 1998
CubistFor profitNDA2Dec 19, 2014
Eugia PharmaFor profitMKTGMay 23, 2011
Eugia PharmaFor profitSYNOct 12, 2023
FreseniusFor profitMKTGMay 11, 2018
FreseniusFor profitSYNMay 11, 2018
HospiraFor profitMKTGSep 15, 2009
Istituto Bio Ita SpaFor profitMKTGMay 31, 2011
MerckFor profitNDA2Dec 19, 2014
Milla PharmsFor profitMKTGJan 13, 2017
MylanFor profitMKTGAug 15, 2014
Nichi-Iko Pharmaceutical Co., Ltd.For profitMKTGFeb 16, 2021
NovartisFor profitMKTGOct 21, 2010
ONESOURCE SPECIALTYFor profitMKTGAug 15, 2014
Provepharm SasFor profitMKTGJan 13, 2017
Qilu Pharmaceutical Co., Ltd.For profitMKTGAug 10, 2018
Qilu Pharmaceutical Co., Ltd.For profitSYNAug 10, 2018
STERISCIENCEFor profitMKTGAug 15, 2014
STERISCIENCEFor profitSYNAug 15, 2014
Sagent Pharmaceuticals, Inc.For profitMKTGFeb 16, 2021
SandozFor profitMKTGOct 21, 2010
SandozFor profitSYNOct 29, 2014
Shandong Lanjin Pharmaceuticals Co.,LtdFor profitMKTGAug 10, 2018
WockhardtFor profitMKTGMar 17, 2017
WyethFor profitNDA—
WyethFor profitNDA2Oct 22, 1993